Valuation: Colinz Laboratories Limited

Market Cap 112M 1.17M 1.03M 959K 882K 1.65M 1.68M 11.38M 4.45M 55.59M 4.41M 4.31M 192M P/E 2024
19.5x
P/E 2025 36.8x
Enterprise Value 63.01M 660K 579K 539K 496K 929K 945K 6.39M 2.5M 31.25M 2.48M 2.42M 108M EV / Sales 2024
0.43x
EV / Sales 2025 2.04x
Free-Float
31.44%
Yield 2024 *
-
Yield 2025 -
06-18 Annjana Dugar, Likhitta Dugar and Antariksh Dugar executed of Share Purchase Agreement to acquire an additional 34.56% stake in Colinz Laboratories Limited from Vijaya Mani for INR 43.5 million, CI
06-18 Annjana Dugar, Likhitta Dugar and Antariksh Dugar proposed to acquire an additional 26% stake in Colinz Laboratories Limited for INR 35.4 million. CI
05-25 Padam Dugar, Annjana Dugar, Likhitta Dugar and Antariksh Dugar acquired 15.01% stake in Colinz Laboratories Limited. CI
04-29 Colinz Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
01-24 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
01-17 Hilsun Foods And Drugs Private Limited signed a letter of intent to acquire Factory Building, Factory Machinery, & Factory Land of Colinz Laboratories Limited for INR 40 million. CI
11-27 Colinz Laboratories Limited Appoints Falguni Kumawat as Company Secretary and Compliance Officer, with Effect from 1 December, 2025 CI
11-08 Colinz Laboratories Limited Announces of Demise Dr. Mani L.S., Founder Director, Company Secretary and Compliance Officer on 7 November 2025 CI
11-03 Colinz Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
31/07/25 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
21/05/25 Colinz Laboratories Limited Appoints Swapnil Jayesh Madiyar as Additional Director, Effective from May 16, 2025 CI
16/05/25 Colinz Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
04/03/25 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
1 day+0.45%
1 week+3.74%
Current month-0.41%
1 month+9.78%
3 months+84.31%
6 months+49.44%
Current year+54.65%
1 week 75.5
Extreme 75.5
85.79
1 month 63.18
Extreme 63.18
87.44
Current year 39.31
Extreme 39.31
87.91
1 year 36.11
Extreme 36.11
87.91
3 years 35.2
Extreme 35.2
88.7
5 years 15.55
Extreme 15.55
88.7
10 years 4.8
Extreme 4.8
88.7
Manager TitleAgeSince
Chief Executive Officer 73 -
Director of Finance/CFO - 20/05/2019
Compliance Officer - 01/12/2025
Director TitleAgeSince
Director/Board Member 73 26/11/1990
Director/Board Member 33 08/08/2024
Director/Board Member 76 08/08/2024
Change 5-day change 1-year change 3-year change Capi.($)
+0.45%+3.74%+72.32%+140.41% 2.17M
+0.15%+1.04%+16.34%+74.17% 49.38B
+0.53%+3.50%+61.24%+112.76% 36.35B
+2.50%+0.21%-5.74%+23.32% 11.87B
-0.81%-4.33%+12.58%+69.24% 11.53B
+0.38%-2.06%+34.70%+131.86% 8.99B
-0.92%-0.35%+48.24%-9.27% 7B
-0.51%-0.85%+11.77%+33.26% 6.76B
-0.52%-2.45%+1.83%+165.65% 6.46B
-1.32%-11.87%-32.46%-0.24% 5.49B
Average -0.01%-0.53%+22.08%+74.11% 14.38B
Weighted average by Cap. +0.21%+0.32%+25.54%+78.22%

Financials

2024 2025
Net sales 70.3M 736K 646K 601K 553K 1.04M 1.05M 7.13M 2.79M 34.86M 2.76M 2.7M 120M 65.28M 683K 600K 558K 514K 963K 979K 6.62M 2.59M 32.37M 2.57M 2.51M 112M
Net income 4.87M 50.94K 44.71K 41.63K 38.29K 71.78K 73.01K 494K 193K 2.41M 191K 187K 8.34M 4.97M 51.98K 45.62K 42.48K 39.07K 73.24K 74.5K 504K 197K 2.46M 195K 191K 8.51M
Net Debt -64.3M -673K -591K -550K -506K -948K -965K -6.53M -2.55M -31.89M -2.53M -2.47M -110M -49.09M -514K -451K -420K -386K -724K -736K -4.98M -1.95M -24.35M -1.93M -1.89M -84.12M
Logo Colinz Laboratories Limited
Colinz Laboratories Ltd. is an India-based company that is engaged in the manufacturing and marketing of pharmaceutical formulations, particularly in the gynecological sector. It is engaged in the manufacturing and marketing various allopathic, ayurvedic, and nutraceuticals pharmaceutical formulations in the dosage forms of tablets, capsules, liquid orals and ointments, among others. The company has specialized products for Gynecology, cardiology, gastroenterology, and others. Its oncology products include imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, and doxorubicin. Its Ayurvedic products include anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, and memory boosters. Its nutraceuticals products include spirulina tabs/caps, spirulina with vitamins & minerals, omega 3 fatty acid caps in softgel, codliver oil with vitamin caps in soft gel, collagen, and glucosamine & chondroitin tabs.
Employees
65
Date Price Change Volume
28/07/26 82.94 +0.45% 2,532
27/07/26 ₹82.57 +5.00% 12,164
24/07/26 ₹78.64 -2.30% 3,101
23/07/26 ₹80.49 +0.45% 394
22/07/26 ₹80.13 -2.28% 1,188
  1. Stock Market
  2. Stocks
  3. COLINZ6 Stock